JW Pharmaceutical
91
7
9
73
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
2.2%
2 terminated/withdrawn out of 91 trials
97.3%
+10.8% vs industry average
45%
41 trials in Phase 3/4
4%
3 of 73 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (91)
A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
Role: lead
to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia
Role: lead
To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects
Role: lead
To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers
Role: lead
To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers
Role: lead
PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers
Role: lead
PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers
Role: lead
Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study
Role: lead
PROGAIN Trial in Gastric Cancer Surgery
Role: collaborator
Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia
Role: lead
Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides
Role: lead
Glycemic Variability of Combination Therapies in T2DM
Role: lead
Efficacy and Safety of Livalozet® in Hypercholesterolemic Patients With and Without Diabetes
Role: lead
Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
Role: lead
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM
Role: lead
Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
Role: lead
To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105
Role: lead
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus
Role: lead
To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet
Role: lead
Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia
Role: lead